Skip to main content
SpringerLink
Log in

Delayed brain metastasis in recurrent hepatocellular carcinoma following liver transplantation: a case report highlighting the predictive value of microvascular invasion

  • Case Report
  • Published:
Clinical Journal of Gastroenterology Aims and scope Submit manuscript

Abstract

Recurrent hepatocellular carcinoma (HCC) poses a significant challenge after liver transplantation, affecting approximately 10–23% of patients with a median onset of 13 months post-transplantation. Extrahepatic involvement, such as lung, bone, adrenal glands, peritoneum, lymph nodes, and central nervous system (CNS), is commonly observed among transplant recipients with HCC recurrence. Notably, vascular invasion (VI), including microvascular invasion (MiVI) and macrovascular invasion (MVI), substantially increase the risk of recurrence by 2.42- and 7.82-fold, respectively. This article presents a unique case of a 72-year-old male patient with a history of HCV-related cirrhosis and HCC who underwent orthotopic liver transplantation (OLT). Six years later, he presented to the emergency department following a fall, which led to the discovery of a pathologic fracture of T7 and an incidental intracranial mass during imaging. Subsequent biopsy confirmed metastatic HCC in the T7 lesion, while magnetic resonance imaging revealed two enhancing brain masses. One mass measured 4.8 cm in the left occipitotemporal lobe, and the other measured 1.7 cm in the right frontal gyrus. Notably, the patient had exhibited MiVI and a mildly elevated alpha-fetoprotein level (AFP) of 7.6 ng/mL at the time of his OLT. This case underscores the predictive value of MiVI in HCC recurrence post-OLT. Accordingly, extended post-transplantation surveillance is crucial for patients with HCC and MiVI. Moreover, this report highlights the uncommon occurrence of delayed brain metastasis following OLT in a patient with HCC.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med. 1996;334(11):693–9.

    Article  CAS  PubMed  Google Scholar 

  2. Roayaie S, Schwartz JD, Sung MW, et al. Recurrence of hepatocellular carcinoma after liver transplant: patterns and prognosis. Liver Transpl. 2004;10(4):534–40.

    Article  PubMed  Google Scholar 

  3. Schreibman IR, Bejarano P, Martinez EJ, et al. Very late recurrence of hepatocellular carcinoma after liver transplantation: case report and literature review. Transplant Proc. 2006;38(9):3140–3.

    Article  CAS  PubMed  Google Scholar 

  4. Yanhan W, Lianfang L, Hao L, et al. Effect of microvascular invasion on the prognosis in hepatocellular carcinoma and analysis of related risk factors: a two-center study. Front Surg. 2021;8: 733343.

    Article  PubMed  PubMed Central  Google Scholar 

  5. Costentin CE, Ferrone CR, Arellano RS, et al. Hepatocellular carcinoma with macrovascular invasion: defining the optimal treatment strategy. Liver Cancer. 2017;6(4):360–74.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Filgueira NA. Hepatocellular carcinoma recurrence after liver transplantation: risk factors, screening and clinical presentation. World J Hepatol. 2019;11(3):261–72.

    Article  PubMed  PubMed Central  Google Scholar 

  7. Mazzaferro V, Llovet JM, Miceli R, et al. Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol. 2009;10(1):35–43.

    Article  PubMed  Google Scholar 

  8. Stras WA, Wasiak D, Lagiewska B, et al. Recurrence of hepatocellular carcinoma after liver transplantation: risk factors and predictive models. Ann Transplant. 2022;27: e934924.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Germani G, Gurusamy K, Garcovich M, et al. Which matters most: number of tumors, size of the largest tumor, or total tumor volume? Liver Transpl. 2011;17(Suppl 2):S58-66.

    Article  PubMed  Google Scholar 

  10. Bharat A, Brown DB, Crippin JS, et al. Pre-liver transplantation locoregional adjuvant therapy for hepatocellular carcinoma as a strategy to improve longterm survival. J Am Coll Surg. 2006;203(4):411–20.

    Article  PubMed  Google Scholar 

  11. Brown DB, Nikolic B, Covey AM, et al. Quality improvement guidelines for transhepatic arterial chemoembolization, embolization, and chemotherapeutic infusion for hepatic malignancy. J Vasc Interv Radiol. 2012;23(3):287–94.

    Article  PubMed  Google Scholar 

  12. Clavien P-A, Lesurtel M, Bossuyt PMM, et al. Recommendations for liver transplantation for hepatocellular carcinoma: an international consensus conference report. Lancet Oncol. 2012;13(1):e11–22.

    Article  PubMed  Google Scholar 

  13. Felga G, Evangelista AS, Salvalaggio PR, et al. Hepatocellular carcinoma recurrence among liver transplant recipients within the Milan criteria. Transplant Proc. 2012;44(8):2459–61.

    Article  CAS  PubMed  Google Scholar 

  14. Park JW, Lee KW, Kim SJ, et al. Outcome of patients with recurrent hepatocellular carcinoma in liver transplantation. Transplant Proc. 2006;38(7):2121–2.

    Article  CAS  PubMed  Google Scholar 

  15. Schlitt HJ, Neipp M, Weimann A, et al. Recurrence patterns of hepatocellular and fibrolamellar carcinoma after liver transplantation. J Clin Oncol. 1999;17(1):324–31.

    Article  CAS  PubMed  Google Scholar 

  16. Foerster F, Hoppe-Lotichius M, Vollmar J, et al. Long-term observation of hepatocellular carcinoma recurrence after liver transplantation at a European transplantation centre. United Eur Gastroenterol J. 2019;7(6):838–49.

    Article  Google Scholar 

  17. Sapisochin G, Bruix J. Liver transplantation for hepatocellular carcinoma: outcomes and novel surgical approaches. Nat Rev Gastroenterol Hepatol. 2017;14(4):203–17.

    Article  PubMed  Google Scholar 

  18. Mehta N, Dodge JL, Roberts JP, et al. Validation of the prognostic power of the RETREAT score for hepatocellular carcinoma recurrence using the UNOS database. Am J Transplant. 2018;18(5):1206–13.

    Article  CAS  PubMed  Google Scholar 

  19. Agopian VG, Harlander-Locke M, Zarrinpar A, et al. A novel prognostic nomogram accurately predicts hepatocellular carcinoma recurrence after liver transplantation: analysis of 865 consecutive liver transplant recipients. J Am Coll Surg. 2015;220(4):416–27.

    Article  PubMed  Google Scholar 

  20. Berry K, Ioannou GN. Serum alpha-fetoprotein level independently predicts posttransplant survival in patients with hepatocellular carcinoma. Liver Transpl. 2013;19(6):634–45.

    Article  PubMed  Google Scholar 

  21. Gouw AS, Balabaud C, Kusano H, et al. Markers for microvascular invasion in hepatocellular carcinoma: where do we stand? Liver Transpl. 2011;17(Suppl 2):S72-80.

    Article  PubMed  Google Scholar 

  22. Yang J-C, Hu J-J, Li Y-X, et al. Clinical applications of liquid biopsy in hepatocellular carcinoma. Front Oncol. 2022;12: 781820.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Hirokawa F, Hayashi M, Miyamoto Y, et al. Outcomes and predictors of microvascular invasion of solitary hepatocellular carcinoma. Hepatol Res. 2014;44(8):846–53.

    Article  CAS  PubMed  Google Scholar 

  24. Roayaie S, Blume IN, Thung SN, et al. A system of classifying microvascular invasion to predict outcome after resection in patients with hepatocellular carcinoma. Gastroenterology. 2009;137(3):850–5.

    Article  PubMed  Google Scholar 

  25. Rodriguez-Peralvarez M, Luong TV, Andreana L, et al. A systematic review of microvascular invasion in hepatocellular carcinoma: diagnostic and prognostic variability. Ann Surg Oncol. 2013;20(1):325–39.

    Article  PubMed  Google Scholar 

  26. Pinheiro RS, Waisberg DR, Nacif LS, et al. Living donor liver transplantation for hepatocellular cancer: an (almost) exclusive Eastern procedure? Transl Gastroenterol Hepatol. 2017;2:68.

    Article  PubMed  PubMed Central  Google Scholar 

  27. Aggarwal A, Te HS, Verna EC, et al. A national survey of hepatocellular carcinoma surveillance practices following liver transplantation. Transplant Direct. 2021;7(1): e638.

    Article  PubMed  Google Scholar 

  28. Berenguer M, Burra P, Ghobrial M, et al. Posttransplant management of recipients undergoing liver transplantation for hepatocellular carcinoma. Working group report from the ILTS transplant oncology consensus conference. Transplantation. 2020;104(6):1143–9.

    Article  PubMed  Google Scholar 

  29. Lee DD, Sapisochin G, Mehta N, et al. Surveillance for HCC after liver transplantation: increased monitoring may yield aggressive treatment options and improved postrecurrence survival. Transplantation. 2020;104(10):2105–12.

    Article  PubMed  Google Scholar 

  30. Kubo S, Nishiguchi S, Hirohashi K, et al. Randomized clinical trial of long-term outcome after resection of hepatitis C virus-related hepatocellular carcinoma by postoperative interferon therapy. Br J Surg. 2002;89(4):418–22.

    Article  CAS  PubMed  Google Scholar 

  31. Kubo S, Nishiguchi S, Hirohashi K, et al. Effects of long-term postoperative interferon-alpha therapy on intrahepatic recurrence after resection of hepatitis C virus-related hepatocellular carcinoma. A randomized, controlled trial. Ann Intern Med. 2001;134(10):963–7.

    Article  CAS  PubMed  Google Scholar 

  32. NCCN (2019) NCCN clinical practice guidelines in oncology (NCCN guidelines). https://www.nccn.org/professionals/physician_gls/default.aspx. Hepatobiliary Cancers. (Version 1). Accessed 9 May 2023.

  33. Du Y, Su T, Ding Y, et al. Effects of antiviral therapy on the recurrence of hepatocellular carcinoma after curative resection or liver transplantation. Hepat Mon. 2012;12(10 HCC):e6031.

    PubMed  PubMed Central  Google Scholar 

  34. Pazgan-Simon M, Simon KA, Jarowicz E, et al. Hepatitis B virus treatment in hepatocellular carcinoma patients prolongs survival and reduces the risk of cancer recurrence. Clin Exp Hepatol. 2018;4(3):210–6.

    Article  PubMed  PubMed Central  Google Scholar 

  35. Lu LC, Lee YH, Chang CJ, et al. Increased expression of programmed death-ligand 1 in infiltrating immune cells in hepatocellular carcinoma tissues after sorafenib treatment. Liver Cancer. 2019;8(2):110–20.

    Article  CAS  PubMed  Google Scholar 

  36. Wu K, Kryczek I, Chen L, et al. Kupffer cell suppression of CD8+ T cells in human hepatocellular carcinoma is mediated by B7–H1/programmed death-1 interactions. Cancer Res. 2009;69(20):8067–75.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Lerut J, Iesari S, Foguenne M, et al. Hepatocellular cancer and recurrence after liver transplantation: what about the impact of immunosuppression? Transl Gastroenterol Hepatol. 2017;2:80.

    Article  PubMed  PubMed Central  Google Scholar 

  38. Rodríguez-Perálvarez M, Tsochatzis E, Naveas MC, et al. Reduced exposure to calcineurin inhibitors early after liver transplantation prevents recurrence of hepatocellular carcinoma. J Hepatol. 2013;59(6):1193–9.

    Article  PubMed  Google Scholar 

  39. Ossami Saidy RR, Postel MP, Pflüger MJ, et al. Minimization of immunosuppressive therapy is associated with improved survival of liver transplant patients with recurrent hepatocellular carcinoma. Cancers (Basel). 2021;13(7):1617.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Hematology and Oncology, Mayo Clinic, 4500 San Pablo Rd., Jacksonville, FL, 32224, USA

    Bhrugun Anisetti, Tucker Coston, Lindsay Gardner, Umair Majeed & Hani Babiker

  2. Department of Radiology, Mayo Clinic, Jacksonville, FL, USA

    Ahmed K. Ahmed

  3. Department of Laboratory Medicine and Pathology, Mayo Clinic, Jacksonville, FL, USA

    Jordan Reynolds

Authors
  1. Bhrugun Anisetti
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ahmed K. Ahmed
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Tucker Coston
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Lindsay Gardner
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Umair Majeed
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Jordan Reynolds
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Hani Babiker
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Bhrugun Anisetti.

Ethics declarations

Conflict of interest

Authors declare that they have no conflicts of interest.

Human and animal rights

All procedures were performed in accordance with the ethical standards in the 1964 Declaration of Helsinki and its later amendments.

Informed consent

This study does not contain patient identifying information.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Anisetti, B., Ahmed, A.K., Coston, T. et al. Delayed brain metastasis in recurrent hepatocellular carcinoma following liver transplantation: a case report highlighting the predictive value of microvascular invasion. Clin J Gastroenterol 16, 864–870 (2023). https://doi.org/10.1007/s12328-023-01839-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12328-023-01839-1

Keywords

Search

Navigation